Hospitalization risks in the treatment of bipolar disorder: Comparison of antipsychotic medications

Bipolar Disorders

Volumn 9, Issue 3, 2007, Pages 252-261

  Gianfrancesco, Frank ^a   Rajagopalan, Kitty ^b   Goldberg, Joseph F ^c,d   Wang, Ruey Hua ^a  

^a HECON Associates Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d SILVER HILL HOSPITAL   (United States)

Author keywords

Atypical antipsychotic; Bipolar manicdisorder; Hospitalization; Putative rapid cycling; Typical antipsychotic

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DRUG THERAPY; FEMALE; HOSPITALIZATION; HUMANS; MALE; PIPERAZINES; RISK FACTORS; RISPERIDONE; THIAZOLES;

EID: 34047274300     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00394.x     Document Type: Article

References (43)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159 (Suppl.): 1-50.
2. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness and efficiency. Br J Psychiatry 1994; 164: 741-746.
3. Haywood TW, Kravitz HM, Grossman LS et al. Predicting the 'revolving door' phenomenon among patients with schizophrenia, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856-861.
4. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993-1000.
5. Maj M, Pirozzi R, Magliano L et al. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
6. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1106-1111.
7. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: A longitudinal follow-up study. Am J Psychiatry 1995; 152: 379-384.
8. Gerding LB, Labbate LA, Measom MO et al. Alcohol dependence and hospitalization in schizophrenia. Schizophr Res 1999; 38: 71-75.
9. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
10. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213-219.
11. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry 1995; 27 (Suppl.): 34-42.
12. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) 2003; 166: 315-332.
13. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59 (Suppl. 3): 21-25.
14. Mojtabai R, Lavelle J, Gibson PJ, Bromet EJ. Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes. Schizophr Bull 2003; 29: 519-530.
15. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psych 2003; 15: 23-31.
16. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv (Chic) 2002; 53: 891-893.
17. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenia patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-269.
18. Brown ES, Thomas NR, Carmody T, Mahadi S, Nejtek VA. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry 2001; 34: 80-81.
19. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156: 863-868.
20. Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: comparison between risperidone, perphenazine and haloperidol. J Clin Psychiatry 1999; 60: 850-856.
21. Buckley PF. Novel antipsychotics and patient care in state hospitals. Ann Pharmacother 1998; 32: 906-914.
22. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: A review. J Clin Psychiatry 1994; 55 (Suppl.): 161-165.
23. Solomon DA, Leon AC, Endicott J et al. Unipolar mania over the course of a 20-year follow-up study. Am J Psychiatry 2003; 160: 2049-2051.
24. Yatham L. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry 2005; 66 (Suppl. 1): 13-17.
25. Das AK, Olfson M, Gameroff MJ. Screening for bipolar disorder in a primary care practice. JAMA 2005; 293: 956-963.
26. Mukherjee S, Shukla S, Woodle J, Rosen AM, Olarte S. Misdiagnosis of schizophrenia in bipolar patients: A multiethnic comparison. Am J Psychiatry 1983; 140: 1571-1574.
27. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of hospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-891.
28. Klinkenberg WD, Calsyn RJ. Predictors of psychiatric hospitalization: A multivariate analysis. Adm Policy Ment Health 1998; 5: 403-410.
29. Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry 2006; 18: 9-17.
30. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with bipolar or manic disorder taking typical and atypical antipsychotics. J Clin Psychiatry 2006; 67: 222-232.
31. Test MA, Burke SS, Wallisch LS. Gender differences of young adults and schizophrenic disorders in community care. Schizophr Bull 1990; 16: 331-344.
32. Marken PA, Stanislav SW, Lacombe S et al. Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacol Bull 1992; 28: 201-205.
33. Olfson M, Mechanic D, Boyer CA et al. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 1999; 187: 721-729.
34. Montgomery P, Kirkpatrick H. Understanding those who seek frequent psychiatric hospitalizations. Arch Psych Nurs 2002; 16: 16-24.
35. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987; 48: 94-97.
36. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 28: 199-206.
37. Lyons JS, O'Mahoney MT, Miller SI et al. Predicting readmission to the psychiatric hospital in a managed care environment: Implications for quality indicators. Am J Psychol 1997; 154: 337-340.
38. Sernyak MJ, Godleski LS, Griffin RA et al. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry 1997; 58: 193-195.
39. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 2001; 39: 302-308.
40. Citrome L, Goldberg JF. The many faces of bipolar disorder. How to tell them apart. Postgrad Med 2005; 117: 19-23.
41. Thomas P. The many forms of bipolar disorder: A modern look at an old illness. Affect Disord 2004; 79 (Suppl. 1): 3-8.
42. Wozniak J. Recognizing and managing bipolar disorder in children. J Clin Psychiatry 2005; 66 (Suppl. 1): 18-23.
43. Keller MB. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry 2006; 67 (Suppl. 1): 5-7.